Esperion Therapeutics (NASDAQ:ESPR) Announces Quarterly Earnings Results, Misses Expectations By $0.06 EPS
by Scott Moore · The Cerbat GemEsperion Therapeutics (NASDAQ:ESPR – Get Free Report) announced its earnings results on Friday. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.06), FiscalAI reports. The firm had revenue of $80.10 million for the quarter, compared to analyst estimates of $84.52 million.
Esperion Therapeutics Price Performance
ESPR stock remained flat at $3.14 during trading on Friday. 7,422,727 shares of the company’s stock traded hands, compared to its average volume of 8,629,511. The stock has a market cap of $808.25 million, a PE ratio of -18.47, a price-to-earnings-growth ratio of 2.56 and a beta of 0.91. Esperion Therapeutics has a 12-month low of $0.69 and a 12-month high of $4.18. The firm’s 50 day moving average price is $2.53 and its two-hundred day moving average price is $3.09.
Analyst Upgrades and Downgrades
A number of analysts have commented on ESPR shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Esperion Therapeutics in a research report on Tuesday, April 21st. Cantor Fitzgerald lowered shares of Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 1st. Needham & Company LLC downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday. HC Wainwright downgraded Esperion Therapeutics from a “buy” rating to a “neutral” rating and set a $3.16 price objective for the company. in a research report on Friday, May 1st. Finally, Citizens Jmp lowered shares of Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 1st. One investment analyst has rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $5.54.
Get Our Latest Stock Analysis on Esperion Therapeutics
Institutional Trading of Esperion Therapeutics
Several hedge funds have recently made changes to their positions in ESPR. Sivia Capital Partners LLC bought a new position in shares of Esperion Therapeutics in the second quarter worth $25,000. Kestra Advisory Services LLC acquired a new position in shares of Esperion Therapeutics in the 4th quarter worth approximately $35,000. Captrust Financial Advisors bought a new stake in shares of Esperion Therapeutics in the 4th quarter worth approximately $40,000. CIBC Bancorp USA Inc. bought a new stake in shares of Esperion Therapeutics in the 3rd quarter worth approximately $56,000. Finally, Cibc World Markets Corp acquired a new stake in Esperion Therapeutics during the fourth quarter valued at approximately $57,000. Institutional investors own 47.39% of the company’s stock.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.
The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.